To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg maraviroc in healthy male Japanese volunteers.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
12
12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
Pfizer Investigational Site
Singapore, Singapore
Plasma and urine maraviroc concentrations for pharmacokinetic analysis
Time frame: pre-48 hrs post dose
Adverse event monitoring
Time frame: Day 0 to Day 3
Bood pressure, pulse rate
Time frame: Day 0, Day 1, and Day 3
Blood and urine safety laboratory tests
Time frame: Day 0 and Day 3
ECG
Time frame: Day 0 and Day 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.